Kazia Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Sydney , march 21, 2024 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with sovargen co., ltd, a biotechnology company specializing in central nervous system (cns) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (fcd t2) and tuberous sclerosis complex (tsc) disease. the underlying cause of fcd t2 and tsc can be traced back to somatic mutations in the pi3k/akt/mtor pathway or mutations in the tsc1 or tsc2 genes, which lead to the overactivation of the mtor pathway.

Sydney, march 13, 2024 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and evt801, at the upcoming annual meeting of the american association of cancer research (aacr) in san diego, california, from 5-10 april 2024. there will be three presentations in total at aacr, including data from the phase 1 study of evt801 in advanced solid cancers.

Paxalisib plus radiotherapy data shows promise for treating patients with pi3k pathway mutation brain metastases sydney , feb. 21, 2024 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part phase i trial. this investigator-initiated trial evaluated the use of paxalisib (an oral pi3k/mtor dual inhibitor) with radiation therapy for the treatment of patients with pi3k pathway mutation brain metastases from solid tumors.

Sydney , jan. 18, 2024 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, mr. robert apple to kazia's board of the directors (the "board") as a non-executive director.

Sydney , dec. 5, 2023 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia) ("kazia" or the "company"), an oncology-focused drug development company, today announced the closing of its previously announced purchase and sale of up to an aggregate of 4,444,445 of the company's american depositary shares ("adss") (or ads equivalents in lieu thereof), each ads representing ten (10) ordinary shares of the company, at a purchase price of $0.45 per ads (or ads equivalent in lieu thereof), in a registered direct offering. the company also issued in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 adss.

Kazia Therapeutics (NASDAQ: KZIA ) stock is on the move Thursday after the company received fast-track designation for its paxalisib program. The FDA granted the drug fast-track designation as it's designed to treat solid tumor brain metastases harboring PI3K pathway mutations.

SYDNEY , Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the upcoming 24th Annual Global Investment Conference, held in New York, NY, from 12 – 14 September 2022.

SYDNEY , Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO), which will be held in person from 9-13 September 2022 in Paris, France.

Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. The post Kazia Therapeutics (KZIA) Stock Soars on FDA Designation appeared first on InvestorPlace.

SYDNEY , May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC Wainwright Global Investment Conference, to be held in person and virtually in Miami, FL, from 23-26 May 2022.

SYDNEY , April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO). The ASCO Annual Meeting will take place virtually and in person from 3-7 June 2022 and will be held in Chicago, IL.

Kazia Therapeutics Ltd (NASDAQ: KZIA) announced it has appointed Karen Krumeich as Chief Financial Officer. These are the details.

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationships with US investors, preparing the company for future expansion and raising the profile of Kazia in global markets. KZA's lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma. The company reports that these results confirm the asset's previously reported safety and efficacy markers, and the company has high hopes that this signals a breakthrough in the treatment of a complex disease of “high unmet need".

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new study at Sunnybrook Health Sciences Centre in Toronto, Ontario. The company's flagship drug, paxalisib, is a candidate in GBM AGILE, a multi-drug platform study designed to identify promising new therapies for glioblastoma.